Antimicrobial Peptides Display Strong Synergy with Vancomycin Against Vancomycin-Resistant E. faecium, S. aureus, and...

Area of Science:

• Microbiology
• Infectious Diseases
• Drug Discovery

Background:

• Antibiotic resistance poses a significant global health threat, necessitating novel therapeutic strategies.
• Existing antibiotics, like vancomycin, face resistance from bacterial strains such as Enterococcus faecium and Staphylococcus aureus.
• Antimicrobial peptides (AMPs) are a promising class of compounds with potential to overcome resistance mechanisms.

Purpose of the Study:

• To investigate the synergistic effects of the antimicrobial peptide P-113 and its derivatives with vancomycin against resistant bacterial strains.
• To characterize the interactions between these peptides, vancomycin, and bacteria using labeled vancomycin.
• To evaluate the ability of the peptides to neutralize lipopolysaccharide (LPS) release induced by antibiotics.

Main Methods:

• Checkerboard method to assess synergistic antimicrobial activity.
• Use of Boron-dipyrro-methene (BODIPY) labeled vancomycin for interaction studies.
• Evaluation of minimal inhibitory concentrations (MICs) and membrane permeabilization.

Main Results:

• Bip-P-113 exhibited the most significant synergistic effects with vancomycin against vancomycin-resistant Enterococcus faecium, Staphylococcus aureus, and wild-type Escherichia coli.
• The peptide demonstrated potent bacterial membrane permeabilization and effective neutralization of LPS release from E. coli.
• BODIPY-vancomycin labeling facilitated characterization of peptide-antibiotic-bacterial interactions.

Conclusions:

• Antimicrobial peptide Bip-P-113 shows strong synergistic potential with vancomycin against challenging bacterial pathogens.
• This peptide offers a promising strategy for developing novel antimicrobial therapies, particularly in combination with glycopeptides.
• The findings contribute to the development of effective treatments against antibiotic-resistant infections.